Company / SG&A per Share
Trevi Therapeutics, Inc. SG&A per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.12
FY2024
5-year range
$0.10 / $0.56
FY2020-FY2024
Trend
+15.2%
vs FY2023
Sector context
#206 of 210
Health Care
What the data says
Among 210 Health Care companies, Trevi Therapeutics, Inc. is in the top 2% for sg&a per share. SG&A per Share returned to growth in FY2024 after 5 years of decline, reaching $0.12.
Based on SEC 10-K filings.
0.12 in FY2024 with a 5-year CAGR of -28.2%.
Improved from $0.16 to $0.12 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -34.1%
- 5-Year CAGR
- -28.2%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 210This company $0.12 Sector average $40.75
▼
-99.7% below sector average
Key checks
Key Insights
- In FY2024, sg&a per share increased 15.2% year-over-year.
- Ranks #206 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2018.
- Lowest sg&a per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.12 | +15.2% |
| FY2023 | $0.10 | -33.7% |
| FY2022 | $0.16 | -62.4% |
| FY2021 | $0.42 | -26.1% |
| FY2020 | $0.56 | -9.6% |
| FY2019 | $0.62 | -93.7% |
| FY2018 | $9.91 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026